"Gastrointestinal Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
| Descriptor ID |
D005765
|
| MeSH Number(s) |
D27.505.954.483
|
| Concept/Terms |
Gastrointestinal Agents- Gastrointestinal Agents
- Agents, Gastrointestinal
- Gastrointestinal Drugs
- Drugs, Gastrointestinal
Gastric Agents- Gastric Agents
- Agents, Gastric
- Gastric Drugs
- Drugs, Gastric
|
Below are MeSH descriptors whose meaning is more general than "Gastrointestinal Agents".
Below are MeSH descriptors whose meaning is more specific than "Gastrointestinal Agents".
This graph shows the total number of publications written about "Gastrointestinal Agents" by people in this website by year, and whether "Gastrointestinal Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 3 | 0 | 3 |
| 2000 | 3 | 1 | 4 |
| 2001 | 4 | 0 | 4 |
| 2002 | 4 | 2 | 6 |
| 2003 | 3 | 0 | 3 |
| 2004 | 4 | 2 | 6 |
| 2005 | 6 | 1 | 7 |
| 2006 | 3 | 3 | 6 |
| 2007 | 6 | 3 | 9 |
| 2009 | 2 | 2 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 6 | 0 | 6 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 5 | 0 | 5 |
| 2015 | 2 | 2 | 4 |
| 2016 | 8 | 1 | 9 |
| 2017 | 6 | 0 | 6 |
| 2018 | 10 | 3 | 13 |
| 2019 | 5 | 0 | 5 |
| 2020 | 3 | 2 | 5 |
| 2021 | 5 | 1 | 6 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 2 | 3 |
| 2024 | 2 | 6 | 8 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gastrointestinal Agents" by people in Profiles.
-
Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study. Inflamm Bowel Dis. 2025 02 06; 31(2):432-441.
-
Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
-
Interrupting inflammatory bowel disease therapy: why, who, when and how to consider medication holidays. Expert Rev Gastroenterol Hepatol. 2024 Oct; 18(10):587-596.
-
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 10 03; 30(10):1776-1787.
-
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
-
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.
-
Real-World Outcomes of Dual Advanced Therapy in Children and Young Adults with Inflammatory Bowel Disease. Dig Dis Sci. 2024 May; 69(5):1826-1833.
-
Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis. Nutr Clin Pract. 2024 Jun; 39(3):634-640.
-
A Look Into the Future: Are We Ready for an Approved Therapy in Celiac Disease? Gastroenterology. 2024 Jun; 167(1):183-193.
-
Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.